Ebenezer Kio, MD
Hematology & Oncology · Goshen, INNPI 1164509535
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,525 of the $39,605 with a category attached, or 82.1%. 25 manufacturers reported payments, led by Novartis at 25.2% of the total. Reporting peaked in 2019 at $15,835 and has fallen 76.3% since, to $3,753 in 2024.
Across 80 payments — averaging $495.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Gilead$7K
- Ipsen Biopharmaceuticals, Inc$6K
- Eli Lilly$5K
- AstraZeneca$4K
- Beigene USA, Inc.$3K
- plus $5K from 19 others
Across 301 payments — averaging $9103.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.3M
- Merck$508K
- Aadi Bioscience, Inc.$245K
- AbbVie$190K
- Beigene, Ltd.$137K
- Corcept Therapeutics$63K
- plus $280K from 13 others
What the payments were for
- Consulting fees$32,52582%
- Travel & lodging$5,09313%
- Food & beverage$1,8485%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $9,969 |
| Gilead(2 entities) | 11 | $6,597 |
| Ipsen Biopharmaceuticals, Inc | 8 | $5,605 |
| Eli Lilly | 3 | $4,888 |
| AstraZeneca | 8 | $4,467 |
| Beigene USA, Inc. | 2 | $2,754 |
| Novocure Inc. | 2 | $2,070 |
| AbbVie | 2 | $1,820 |
| Beigene, Ltd. | 1 | $525 |
| Amgen | 7 | $160 |
| AVEO Pharmaceuticals, Inc. | 1 | $125 |
| Tempus AI, Inc | 1 | $94 |
| Adaptive Biotechnologies Corporation | 1 | $90 |
| Bristol Myers Squibb | 3 | $79 |
| Rigel Pharmaceuticals, Inc. | 1 | $65 |
| Astellas Pharma US Inc | 2 | $45 |
| Johnson & Johnson | 2 | $43 |
| ADC Therapeutics America, Inc. | 1 | $42 |
| Aadi Bioscience, Inc. | 2 | $37 |
| Incyte Corporation | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Merck | 2 | $22 |
| Eisai Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,605 in reported general payments places this provider in the 85th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 24 | $362,155 |
| JakafiRuxolitinib Phosphate | 11 | $195,578 |
| Abiraterone Acetate | 13 | $14,267 |
| EliquisApixaban | 16 | $11,191 |
| Anastrozole | 27 | $824 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 16 | $790 |
| Dexamethasone | 17 | $527 |
| Calcitriol | 22 | $332 |
| Prochlorperazine Maleate | 28 | $270 |
| Ondansetron OdtOndansetron | 23 | $247 |
| Potassium Chloride | 25 | $240 |
| Hydroxyurea | 11 | $180 |
| Levothyroxine Sodium | 12 | $136 |
| Prednisone | 15 | $107 |
| Methylprednisolone | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $2,754 | $362,15524 claims |
| Incyte CorporationJakafi | $33 | $195,57811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Goshen
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Chandler ParkCorydon$661K
- Neel ShahDyer$464K
- Ahad SadiqFort Wayne$430K
- Ajay KandraMadison$408K
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.